StemCells to acquire subsidiaries, assets of U.K. biotech firm

03/2/2009 | American City Business Journals

London-based Stem Cell Sciences has agreed to sell its operating units and certain related assets to StemCells for about $715,000 in cash and 2.65 million shares of stock. The deal, which was cleared by both firms' boards of directors, covers stem cell technologies as well as expertise and infrastructure for cell-based assays used in treatment discovery and testing.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ